Hypoparathyroidism Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Hypoparathyroidism Treatment Market report segments the industry into By Product Type (Parathyroid Hormone Replacement, Vitamin D Analogue, Calcium Supplements, Others (Thiazide Diuretics, Magnesium Supplements)), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Platforms), and Geography (North America, Europe, Asia-Pacific, and more).

Hypoparathyroidism Treatment Market Size

Compare market size and growth of Hypoparathyroidism Treatment Market with other markets in Healthcare Industry

Hypoparathyroidism Treatment Market Analysis

The Hypoparathyroidism Treatment Market size is estimated at USD 0.63 billion in 2025, and is expected to reach USD 1.49 billion by 2030, at a CAGR of 4% during the forecast period (2025-2030).

Factors such as the rising incidence of hypoparathyroid disorders and the growing demand for innovative treatments are set to propel market growth during the forecast period. For example, an April 2024 article in the Endocrinology and Metabolism journal highlighted that using rhPTH(1-84) or PTH(1-34) as a substitute for the missing hormone in hypoparathyroidism treatment reduced dependence on traditional therapies. Palopegteriparatide, a prodrug, guarantees a steady release of PTH(1-34), designed to keep parathyroid hormone (PTH) levels stable within the physiological range for 24 hours. Hence, the increasing adoption of these new therapies is anticipated to fuel market growth.

Moreover, the rise of conferences and events focusing on treatment advancements in hypoparathyroidism is likely to bolster market growth. For instance, the 25th European Congress of Endocrinology, held in May 2023, delved into case studies in which ADH1-related hypoparathyroidism patients need meticulous management through conventional therapy to mitigate risks like hypercalciuria and nephrolithiasis, even if this doesn't tackle the condition's root cause. The conference also provided a succinct overview of hypoparathyroidism and discussed management guidelines for both established and emerging treatments. Thus, these events are poised to catalyze advancements in hypoparathyroidism treatments, boosting market growth.

In conclusion, with the influx of advanced treatment modalities and a rise in conferences spotlighting hypoparathyroidism treatment trends, this market is set to lead growth. Yet, potential adverse reactions and side effects from hypoparathyroid treatments could pose challenges to this growth trajectory.

Hypoparathyroidism Treatment Industry Overview

The hypoparathyroidism treatment market is semi-consolidated due to the presence of several companies operating globally and regionally. The key players are involved in various strategic activities such as partnerships, collaborations, product launches, etc., among others. The competitive landscape includes an analysis of a few international and local companies. A few of the key competitors are EnteraBio Ltd., Amgen Inc., Ascendis Pharma A/S, F. Hoffmann-La Roche AG, Zhejiang NHU Co., Ltd., and Teva Pharmaceuticals, among others.

Hypoparathyroidism Treatment Market Leaders

  1. F. Hoffmann-La Roche Ltd

  2. Teva Pharmaceutical Industries Ltd.

  3. Amgen Inc.

  4. Zhejiang NHU Co., Ltd.

  5. EnteraBio Ltd.

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

Hypoparathyroidism Treatment Market News

  • August 2024: Ascendis Pharma A/S received the United States (U.S) Food & Drug Administration (FDA) approval for its YORVIPATH (palopegteriparatide; developed as TransCon PTH) for treating hypoparathyroidism in adults. YORVIPATH, a prodrug of parathyroid hormone (PTH[1-34]), is administered once daily and is designed to ensure continuous exposure to released PTH throughout the 24-hour dosing period.
  • May 2024: The United States Food and Drug Administration (FDA) awarded fast-track designation to eneboparatide, an experimental drug aimed at treating hyperparathyroidism. The phase 3 Calypso trial is investigating Eneboparatide.

Hypoparathyroidism Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Cases Of Hypoparathyroid Disorders
    • 4.2.2 High Demand for Novel Hypoparathyroidism Treatment
  • 4.3 Market Restraints
    • 4.3.1 Increase in Side Effects Associated with Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Product Type
    • 5.1.1 Parathyroid Hormone Replacement
    • 5.1.2 Vitamin D Analogue
    • 5.1.3 Calcium Supplements
    • 5.1.4 Others (Thiazide Diuretics, Magnesium Supplements)
  • 5.2 By Route of Administration
    • 5.2.1 Oral
    • 5.2.2 Parenteral
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Platforms
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 EnteraBio Ltd.
    • 6.1.2 Amgen Inc.
    • 6.1.3 F. Hoffmann-La Roche AG
    • 6.1.4 Zhejiang NHU Co., Ltd.
    • 6.1.5 Teva Pharmaceuticals
    • 6.1.6 Abbott
    • 6.1.7 Pfizer Inc.
    • 6.1.8 GSK plc
    • 6.1.9 Ascendis Pharma
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Hypoparathyroidism Treatment Industry Segmentation

As per the scope of the report, hypoparathyroidism, a rare endocrine disorder, arises from dysfunction of the parathyroid glands, leading to a deficiency in parathyroid hormone. This deficiency subsequently causes hypocalcemia, hyperphosphatemia, and heightened neuromuscular irritability.

The hypoparathyroidism treatment market is segmented by product type, route of administration, end-user, and geography. By product type, the market is segmented into parathyroid hormone, vitamin D analogue, calcium supplements, and others. By route of administration, the market is segmented into oral and parenteral. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online sales. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD) for the above segments.

By Product Type Parathyroid Hormone Replacement
Vitamin D Analogue
Calcium Supplements
Others (Thiazide Diuretics, Magnesium Supplements)
By Route of Administration Oral
Parenteral
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Platforms
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Parathyroid Hormone Replacement
Vitamin D Analogue
Calcium Supplements
Others (Thiazide Diuretics, Magnesium Supplements)
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Platforms
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Hypoparathyroidism Treatment Market Research FAQs

How big is the Hypoparathyroidism Treatment Market?

The Hypoparathyroidism Treatment Market size is expected to reach USD 0.63 billion in 2025 and grow at a CAGR of 4% to reach USD 1.49 billion by 2030.

What is the current Hypoparathyroidism Treatment Market size?

In 2025, the Hypoparathyroidism Treatment Market size is expected to reach USD 0.63 billion.

Who are the key players in Hypoparathyroidism Treatment Market?

F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Amgen Inc., Zhejiang NHU Co., Ltd. and EnteraBio Ltd. are the major companies operating in the Hypoparathyroidism Treatment Market.

Which is the fastest growing region in Hypoparathyroidism Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Hypoparathyroidism Treatment Market?

In 2025, the North America accounts for the largest market share in Hypoparathyroidism Treatment Market.

What years does this Hypoparathyroidism Treatment Market cover, and what was the market size in 2024?

In 2024, the Hypoparathyroidism Treatment Market size was estimated at USD 0.60 billion. The report covers the Hypoparathyroidism Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Hypoparathyroidism Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Hypoparathyroidism Treatment Industry Report

Statistics for the 2025 Hypoparathyroidism Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hypoparathyroidism Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Access Report